{"id":"vancomycin-ii","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Nephrotoxicity"},{"rate":"1-5%","effect":"Ototoxicity"},{"rate":"10-15%","effect":"Red man syndrome (flushing, pruritus)"},{"rate":"3-7%","effect":"Phlebitis at infusion site"},{"rate":"1-3%","effect":"Fever"},{"rate":"1-2%","effect":"Thrombocytopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Vancomycin II is a glycopeptide antibiotic that targets the bacterial peptidoglycan layer, a critical structural component of gram-positive bacterial cell walls. By binding to D-alanyl-D-alanine residues on peptidoglycan precursors, it prevents the cross-linking reactions necessary for cell wall integrity. This leads to cell wall instability, leakage of cellular contents, and bacterial cell death.","oneSentence":"Vancomycin II inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors, preventing cross-linking and causing cell wall disruption.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:41:24.718Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Serious gram-positive bacterial infections including methicillin-resistant Staphylococcus aureus (MRSA)"},{"name":"Clostridium difficile-associated diarrhea"},{"name":"Endocarditis"},{"name":"Sepsis caused by susceptible gram-positive organisms"}]},"trialDetails":[{"nctId":"NCT06306014","phase":"PHASE1, PHASE2","title":"Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2024-05-07","conditions":"Clostridioides Difficile Infection, Recurrent Infection","enrollment":56},{"nctId":"NCT03785210","phase":"PHASE2","title":"Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-06-05","conditions":"Hepatocellular Carcinoma, Hepatocellular Cancer, Metastatic Pancreatic Cancer","enrollment":22},{"nctId":"NCT04729322","phase":"PHASE2","title":"Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-02-22","conditions":"Metastatic Colorectal Adenocarcinoma, Metastatic Small Intestinal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8","enrollment":15},{"nctId":"NCT06817031","phase":"PHASE2","title":"Maternal Probiotic Intervention to Improve Gut Health - Trial II - Bangladesh","status":"ENROLLING_BY_INVITATION","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2025-04-20","conditions":"Environmental Enteric Dysfunction","enrollment":144},{"nctId":"NCT06126731","phase":"PHASE1, PHASE2","title":"Combination Study of Antibiotics With Enzalutamide (PROMIZE)","status":"RECRUITING","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2023-11-02","conditions":"Metastatic Castration-Resistant Prostate Cancer (mCRPC)","enrollment":39},{"nctId":"NCT07134790","phase":"PHASE2","title":"Maternal Probiotic Intervention to Improve Gut Health - Trial II - Burkina Faso (MPIGH-II)","status":"RECRUITING","sponsor":"University Ghent","startDate":"2025-07-30","conditions":"Environmental Enteric Dysfunction (EED)","enrollment":144},{"nctId":"NCT05632315","phase":"PHASE2","title":"PMT for MDRO Decolonization","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2024-08-19","conditions":"Multidrug Resistant Bacterial Infection, Enterobacteriaceae Infections, Pseudomonas Aeruginosa","enrollment":150},{"nctId":"NCT07207434","phase":"PHASE2","title":"Maternal Probiotic Intervention to Improve Gut Health-Trial II-Pakistan","status":"RECRUITING","sponsor":"Aga Khan University","startDate":"2025-08-30","conditions":"Environmental Enteric Dysfunction (EED), Stunting","enrollment":144},{"nctId":"NCT05695261","phase":"PHASE2","title":"Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients","status":"RECRUITING","sponsor":"Rima Rachid","startDate":"2023-06-08","conditions":"Allergy, Peanut, Peanut Allergy, Peanut Hypersensitivity","enrollment":37},{"nctId":"NCT04500275","phase":"PHASE4","title":"Topical Vancomycin Over Sternal Edge in Cardiac Surgery","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2020-07-01","conditions":"Sternal Wound Infection","enrollment":360},{"nctId":"NCT04983901","phase":"PHASE2","title":"PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-09-14","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm","enrollment":100},{"nctId":"NCT05354102","phase":"PHASE1","title":"A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biomica Ltd.","startDate":"2022-05-01","conditions":"Non-small Cell Lung Cancer, Melanoma, Renal Cell Carcinoma","enrollment":11},{"nctId":"NCT04648696","phase":"PHASE4","title":"Safety and Outcomes Associated With Continuous Versus Intermittent Infusion Vancomycin","status":"TERMINATED","sponsor":"Wake Forest University Health Sciences","startDate":"2021-03-03","conditions":"Infection","enrollment":8},{"nctId":"NCT05156437","phase":"PHASE4","title":"Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL)","status":"ENROLLING_BY_INVITATION","sponsor":"Vinay Badhwar","startDate":"2022-03-16","conditions":"Endocarditis","enrollment":20},{"nctId":"NCT03485950","phase":"PHASE2","title":"Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-05-16","conditions":"Other Infectious Diseases","enrollment":100},{"nctId":"NCT03388268","phase":"PHASE4","title":"TOX NEG Trial: Clostridium Difficile Diagnosis and Treatment","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2017-12-29","conditions":"Clostridium Difficile Infection, Diarrhea","enrollment":15},{"nctId":"NCT01252732","phase":"PHASE3","title":"Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection","status":"COMPLETED","sponsor":"Melinta Therapeutics, Inc.","startDate":"2010-12","conditions":"Wound Infection, Abscess, Systemic Inflammation","enrollment":1019},{"nctId":"NCT03643887","phase":"PHASE2","title":"Phase II Trial of Fecal Microbiota Transplant (FMT) for VRE and CRE Patients","status":"WITHDRAWN","sponsor":"University of Wisconsin, Madison","startDate":"2022-09-01","conditions":"Clostridium Difficile Infection","enrollment":""},{"nctId":"NCT01119105","phase":"PHASE2","title":"Study Comparing the Safety and Efficacy of Two Doses of BC-3781 vs Vancomycin in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)","status":"COMPLETED","sponsor":"Nabriva Therapeutics AG","startDate":"2010-05","conditions":"Bacterial Infections, Infection","enrollment":210},{"nctId":"NCT03063437","phase":"PHASE2","title":"A Trial of Encapsulated Fecal Microbiota for Vancomycin Resistant Enterococcus Decolonization","status":"COMPLETED","sponsor":"Microbiome Health Research Institute","startDate":"2017-08-17","conditions":"Antibiotic Resistant Strain","enrollment":9},{"nctId":"NCT04025567","phase":"PHASE2","title":"Vancomycin in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLC) Oral","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2020-03-12","conditions":"Metastatic Hepatocellular Carcinoma, Hepatocellular Carcinoma","enrollment":""},{"nctId":"NCT01513239","phase":"PHASE3","title":"A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-02-01","conditions":"Clostridium Difficile Infection","enrollment":1203},{"nctId":"NCT02168816","phase":"PHASE2","title":"Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for Osteomyelitis","status":"TERMINATED","sponsor":"Loyola University","startDate":"2014-03-19","conditions":"Osteomyelitis","enrollment":30},{"nctId":"NCT02092935","phase":"PHASE2","title":"A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)","status":"COMPLETED","sponsor":"Summit Therapeutics","startDate":"2014-04","conditions":"Clostridium Difficile Infection","enrollment":100},{"nctId":"NCT01226992","phase":"PHASE2, PHASE3","title":"Oral Vancomycin Followed by Fecal Transplant Versus Tapering Oral Vancomycin","status":"TERMINATED","sponsor":"University Health Network, Toronto","startDate":"2010-10","conditions":"Recurrent Clostridium Difficile Infection, Laboratory Confirmed Clostridium Difficile Infection","enrollment":81},{"nctId":"NCT00003805","phase":"PHASE3","title":"Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"1997-11","conditions":"Bone Marrow Suppression, Fever, Sweats, and Hot Flashes, Infection","enrollment":859},{"nctId":"NCT00057369","phase":"PHASE2","title":"Safety and Efficacy of Dalbavancin Versus Vancomycin in the Treatment of Catheter-Related Bloodstream Infections","status":"UNKNOWN","sponsor":"Vicuron Pharmaceuticals","startDate":"2001-02","conditions":"Bacteremia","enrollment":88}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["glycopeptide antibiotic"],"phase":"marketed","status":"active","brandName":"Vancomycin II","genericName":"Vancomycin II","companyName":"Wake Forest University Health Sciences","companyId":"wake-forest-university-health-sciences","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vancomycin II inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors, preventing cross-linking and causing cell wall disruption. Used for Serious gram-positive bacterial infections including methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile-associated diarrhea, Endocarditis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}